Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Oligo-residual Intracranial Disease After First-line Third-generation EGFR Inhibitors: a Multicenter, Randomized Clinical Trial.

NCT06020066 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06020066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06020066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Oligo-residual Intracranial Disease After First-line Third-generation EGFR Inhibitors: a Multicenter, Randomized Clinical Trial.
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 10, 2023
Completion date
August 10, 2028
Enrollment
202 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, non-small cell lung cancer